Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
← catalyst calendarNCT06801834 · readout ≤ 1,169 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
695estimated
Sites
220
Countries
Argentina, Australia, Belgium +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-04 | actual | When the study began enrolling |
| Primary completion | Oct 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
- Drug: Sacituzumab Govitecan (SG) — also filed as Trodelvy®, GS-0132, IMMU 132
- Drug: Topotecan
- Drug: Amrubicin (Japan only)
- Drug: Lurbinectedin (regions/countries where approved and available)
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to 4.5 years
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed